Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OKYO | US
0.02
1.32%
Healthcare
Biotechnology
30/06/2023
13/04/2026
1.53
1.49
1.66
1.47
OKYO Pharma Limited a preclinical biopharmaceutical company engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201 a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London the United Kingdom.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
59.2%1 month
52.1%3 months
82.3%6 months
91.9%-
-
14.11
-1.08
0.43
-4.29
-
-
-15.75M
51.77M
51.77M
-
-
-
-
-2.97K
5.77
0.86
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.28
Range1M
0.29
Range3M
1.76
Rel. volume
1.24
Price X volume
182.83K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ImmuCell Corporation | ICCC | Biotechnology | 7.11 | 55.69M | 0.49% | n/a | 67.52% |
| PEPG | PEPG | Biotechnology | 1.69 | 55.08M | 3.05% | n/a | 12.52% |
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 1.02 | 54.03M | -2.86% | n/a | 35.68% |
| TPST | TPST | Biotechnology | 2.14 | 53.94M | 4.39% | n/a | 119.58% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.257 | 53.51M | 2.31% | n/a | 122.82% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 6.48 | 51.59M | 6.06% | n/a | -6472.02% |
| Akari Therapeutics Plc | AKTX | Biotechnology | 4.2475 | 51.58M | 10.90% | n/a | -27.01% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.61 | 49.87M | 3.21% | n/a | 1.95% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 14.5 | 49.43M | 0.52% | n/a | 3.14% |
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.32 | 49.23M | -2.74% | n/a | 7.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.29 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.11 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 82.33 | 72.80 | Par |
| Debt to Equity | -1.08 | -1.23 | Cheaper |
| Debt to Assets | 0.43 | 0.25 | Expensive |
| Market Cap | 51.77M | 3.66B | Emerging |